Related Experiment Videos
Targeting macrophages with microspheres containing cytokine-neutralizing antibodies prevents lethality in
C W Oettinger1, M D'Souza, G V Milton
1Dialysis Clinic, Inc., Atlanta, GA 30308, USA. coettinger@aol.com
Abstract:
Macrophages release proinflammatory cytokines in response to infection that play a critical role in the pathophysiology of septic shock. We propose that targeting cytokine-neutralizing antibodies using albumin microspheres to macrophages will be more beneficial than the soluble form in reducing mortality related to peritonitis. In this study, we compared the distribution pattern of microspheres in infected and noninfected animals, evaluated the amount of microsphere taken up by peritoneal macrophages in vitro, and compared the efficacy of soluble and microsphere forms of cytokine-neutralizing antibodies in preventing lethality caused by Escherichia coli-induced peritonitis. The results indicate that twice the amount of microspheres accumulates near the site of infection (the peritoneal cavity), and 70% of the microspheres exposed to peritoneal macrophages were phagocytosed in 1 h. Treatment with the microsphere form of cytokine-neutralizing antibodies was more efficacious than using the soluble form in preventing lethality induced by E. coli. Immediate treatment was more efficacious than delayed treatment in the absence of gentamicin, whereas immediate and delayed treatment were equally efficacious in the presence of gentamicin. The combination of microspheres containing neutralizing antibodies to tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) protected 100% of the animals, whereas either one alone protected only 60%-90% of the animals from lethality caused by E. coli-induced peritonitis. In conclusion, the microsphere form of neutralizing antibodies to TNF-alpha IL-1beta may be an effective therapeutic agent in the treatment of septic shock caused by peritonitis.
Insights
Targeting cytokine-neutralizing antibodies with microspheres effectively reduced mortality in E. coli peritonitis. This novel approach showed superior efficacy compared to soluble antibodies in treating septic shock.
Area of Science:
- Immunology
- Biomedical Engineering
- Pharmacology
Background:
- Septic shock, a life-threatening condition, involves proinflammatory cytokines released by macrophages.
- Current treatments for peritonitis-induced septic shock have limitations in efficacy.
Purpose of the Study:
- To evaluate the efficacy of cytokine-neutralizing antibodies encapsulated in albumin microspheres for treating Escherichia coli-induced peritonitis.
- To compare the therapeutic benefits of microsphere-delivered antibodies versus soluble antibodies.
Main Methods:
- Compared microsphere distribution in infected vs. non-infected animals.
- Assessed microsphere phagocytosis by peritoneal macrophages in vitro.
- Evaluated survival rates in response to soluble and microsphere antibody treatments.
Main Results:
- Microspheres showed enhanced accumulation in the peritoneal cavity (infection site).
- Peritoneal macrophages readily phagocytosed 70% of exposed microspheres within 1 hour.
- Microsphere-delivered antibodies significantly improved survival compared to soluble forms.
- Combined antibodies against TNF-alpha and IL-1beta in microspheres achieved 100% protection.
Conclusions:
- Albumin microspheres serve as an effective delivery system for cytokine-neutralizing antibodies to macrophages.
- This targeted delivery enhances therapeutic outcomes in E. coli peritonitis.
- Microsphere-encapsulated antibodies, particularly dual-targeting TNF-alpha and IL-1beta, represent a promising strategy for septic shock treatment.